Skip to content

Aldosterone, Microvascular Function and Salt-sensitivity

Aldosterone-induced Microvascular Dysfunction as a Cause of Salt-sensitivity in Obesity?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02068781
Enrollment
40
Registered
2014-02-21
Start date
2014-07-31
Completion date
2016-10-31
Last updated
2017-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Obesity, Hypertension, Insulin Resistance, Metabolic Syndrome, Sodium-sensitivity

Brief summary

Currently, the incidence of obesity and obesity-related disorders is reaching epidemic proportions, which entails an increasing burden for health care systems. The association of obesity with other risk factors for type 2 diabetes mellitus and cardiovascular disease, such as insulin resistance and hypertension, is often referred to as the metabolic syndrome. During recent years, salt-sensitivity of blood pressure has emerged as an additional cardiovascular risk factor that is related to obesity and other key components of the metabolic syndrome. The underlying pathophysiological mechanisms of these interrelationships are complex and incompletely elucidated. Microvascular dysfunction has been proposed as a link between insulin resistance and hypertension in obese individuals. In addition, impairment of microvascular function was found to be associated with salt-sensitivity of blood pressure. Increased aldosterone levels, as observed in obese individuals, might be a cause of microvascular dysfunction-induced salt-sensitivity and insulin resistance. Aldosterone not only gives rise to sodium-retention in the distal tubule of the kidney, but was also found to impair endothelial function and thus lower NO-availability, which is characteristic of microvascular dysfunction. In addition, elevated aldosterone levels are associated with both hypertension and insulin resistance, which is illustrated in patients with primary aldosteronism, but also in the general population. The investigators hypothesize that increased aldosterone levels in obese individuals lead to impairment of microvascular function through reduction of NO-availability. This microvascular dysfunction is suggested to play a central role in the pathogenesis of salt-sensitive hypertension and insulin resistance.

Interventions

DIETARY_SUPPLEMENTLow-sodium diet

50 mmol NaCl per 24h

DIETARY_SUPPLEMENTHigh-sodium diet

250 mmol NaCl per 24h

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Obese individuals * Age 18-65 years * Caucasian * Waist circumference \> 102 cm (men)/\> 88 cm (women) Lean individuals * Age 18-65 years * Caucasian * Waist circumference \< 94 cm (men)/\< 80 cm (women)

Exclusion criteria

Obese/lean individuals * Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death) * Diabetes mellitus/impaired glucose metabolism (fasting glucose values \> 5.6 mmol/L * Stage 3 hypertension (blood pressure \> 180/110 mm Hg) * Unstable or severe pulmonary disease * Unstable or severe thyroid disorders * Inflammatory diseases * Smoking * Alcohol use \> 2 U/day (women)/\> 3 U/day (men) * Use of antihypertensive, lipid-lowering or glucose-lowering medications * Use of corticosteroids and regular use of NSAIDs * eGFR\< 60 mL/min * Impairment of hepatic function * Pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
Difference in capillary recruitment between low- and high sodium dietsOne week low-sodium diet; wash-out period of two weeks; one week high-sodium diet; order of respective diets is randomized

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026